Related Experiment Videos
[Pulmonary hypertension in rheumatic diseases]
P Manganelli1, F Salaffi, M Carotti
1II Divisione Medica e Reumatologia, Azienda Ospedaliera, Parma.
Minerva Medica
|August 5, 1999
Summary
Pulmonary hypertension (PH) in rheumatic diseases (RD) can stem from direct artery damage or lung fibrosis. Early detection via echocardiography and treatments like immunosuppressants are crucial for managing this severe complication.
Area of Science:
- Rheumatology
- Cardiology
- Pulmonology
Context:
- Rheumatic diseases (RD) are associated with significant pulmonary hypertension (PH) risk.
- PH in RD can arise from direct pulmonary artery damage (isolated PH) or interstitial lung disease.
- Systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are key RD with PH associations.
Purpose:
- To outline the causes, clinical presentation, diagnostic methods, and therapeutic strategies for PH in rheumatic diseases.
- To highlight the distinct pathophysiological mechanisms of PH in different RD subtypes.
- To emphasize the importance of early diagnosis and management of PH in RD patients.
Summary:
- PH in RD presents with diverse etiologies, including occlusive arteriopathy in isolated PH and fibrosis-related PH.
- Doppler echocardiography is the primary non-invasive tool for PH evaluation in RD.
- Treatment involves corticosteroids, immunosuppressants, vasodilators, anticoagulants, and potentially lung transplantation.
Impact:
- Improved understanding of PH pathogenesis in RD.
- Enhanced diagnostic capabilities through echocardiography.
- Guidance for multidisciplinary treatment approaches, including immunosuppression and advanced therapies.